revolution medicines - RVMD
RVMD
Close Chg Chg %
56.78 -0.03 -0.05%
Closed Market
56.75
-0.03 (0.05%)
Volume: 1.17M
Last Updated:
Nov 22, 2024, 4:00 PM EDT
Company Overview: revolution medicines - RVMD
RVMD Key Data
Open $57.06 | Day Range 56.39 - 57.41 |
52 Week Range 20.98 - 62.40 | Market Cap $9.55B |
Shares Outstanding 168.22M | Public Float 141.01M |
Beta 1.40 | Rev. Per Employee N/A |
P/E Ratio N/A | EPS -$3.59 |
Yield 0.00% | Dividend N/A |
EX-DIVIDEND DATE | SHORT INTEREST N/A |
AVERAGE VOLUME 1.60M |
RVMD Performance
1 Week | 2.94% | ||
1 Month | 22.25% | ||
3 Months | 30.04% | ||
1 Year | 162.97% | ||
5 Years | N/A |
RVMD Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
14
Full Ratings ➔
About revolution medicines - RVMD
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
RVMD At a Glance
Revolution Medicines, Inc.
700 Saginaw Drive
Redwood City, California 94063
Phone | 1-650-481-6801 | Revenue | 11.58M | |
Industry | Pharmaceuticals: Other | Net Income | -436,367,000.00 | |
Sector | Health Technology | Employees | 378 | |
Fiscal Year-end | 12 / 2024 | |||
View SEC Filings |
RVMD Valuation
P/E Current | N/A |
P/E Ratio (with extraordinary items) | N/A |
P/E Ratio (without extraordinary items) | N/A |
Price to Sales Ratio | 280.236 |
Price to Book Ratio | 2.586 |
Price to Cash Flow Ratio | N/A |
Enterprise Value to EBITDA | -3.097 |
Enterprise Value to Sales | 127.818 |
Total Debt to Enterprise Value | 0.059 |
RVMD Efficiency
Revenue/Employee | 30,634.921 |
Income Per Employee | -1,154,410.053 |
Receivables Turnover | 9.234 |
Total Asset Turnover | 0.008 |
RVMD Liquidity
Current Ratio | 13.064 |
Quick Ratio | 13.064 |
Cash Ratio | 12.881 |
RVMD Profitability
Gross Margin | 19.611 |
Operating Margin | -4,207.124 |
Pretax Margin | -3,798.713 |
Net Margin | -3,768.282 |
Return on Assets | -29.819 |
Return on Equity | -34.751 |
Return on Total Capital | -22.797 |
Return on Invested Capital | -32.941 |
RVMD Capital Structure
Total Debt to Total Equity | 4.816 |
Total Debt to Total Capital | 4.594 |
Total Debt to Total Assets | 4.211 |
Long-Term Debt to Equity | 4.412 |
Long-Term Debt to Total Capital | 4.209 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Revolution Medicines - RVMD
Collapse All in section
All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
---|---|---|---|---|---|
Sales/Revenue
| 42.98M | 29.39M | 35.38M | 11.58M | |
Sales Growth
| -14.10% | -31.62% | +20.38% | -67.27% | |
Cost of Goods Sold (COGS) incl D&A
| - | 7.33M | 9.66M | 9.31M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 6.54M | 7.33M | 9.66M | 9.31M | |
Depreciation
| 5.48M | 6.26M | 8.59M | 8.24M | |
Amortization of Intangibles
| 1.07M | 1.07M | 1.07M | 1.07M | |
COGS Growth
| - | - | +31.70% | -3.59% | - |
Gross Income
| - | 22.06M | 25.72M | 2.27M | |
Gross Income Growth
| - | - | +16.62% | -91.17% | - |
Gross Profit Margin
| - | +75.05% | +72.71% | +19.61% |
2020 | 2021 | 2022 | 2023 | 5-year trend | |
---|---|---|---|---|---|
SG&A Expense
| 147.13M | 210.07M | 284.00M | 489.46M | |
Research & Development
| 128.57M | 182.80M | 248.03M | 417.03M | |
Other SG&A
| 18.56M | 27.27M | 35.97M | 72.42M | |
SGA Growth
| +46.81% | +42.77% | +35.20% | +72.34% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | (115.00K) | - |
EBIT after Unusual Expense
| (110.70M) | (188.01M) | (258.28M) | (487.07M) | |
Non Operating Income/Expense
| 2.24M | 929.00K | 9.15M | 47.18M | |
Non-Operating Interest Income
| 2.24M | 929.00K | 9.15M | 47.48M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | 71.00K | 12.00K | - |
Interest Expense Growth
| - | -33.02% | -83.10% | -100.00% | |
Gross Interest Expense
| - | - | 71.00K | 12.00K | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (108.53M) | (187.09M) | (249.13M) | (439.89M) | |
Pretax Income Growth
| -108.56% | -72.39% | -33.16% | -76.57% | |
Pretax Margin
| -252.50% | -636.58% | -704.14% | -3,798.71% | |
Income Tax
| - | (371.00K) | (420.00K) | (3.52M) | |
Income Tax - Current - Domestic
| - | - | (371.00K) | 112.00K | - |
Income Tax - Current - Foreign
| - | - | - | 212.00K | - |
Income Tax - Deferred - Domestic
| - | - | - | (3.87M) | - |
Income Tax - Deferred - Foreign
| - | - | - | 17.00K | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (108.16M) | (187.09M) | (248.71M) | (436.37M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (108.16M) | (187.09M) | (248.71M) | (436.37M) | |
Net Income Growth
| -126.92% | -72.98% | -32.93% | -75.46% | |
Net Margin Growth
| -251.63% | -636.58% | -702.95% | -3,768.28% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (108.16M) | (187.09M) | (248.71M) | (436.37M) | |
Preferred Dividends
| - | - | - | 2.22M | - |
Net Income Available to Common
| (110.38M) | (187.09M) | (248.71M) | (436.37M) | |
EPS (Basic)
| -1.6573 | -2.5697 | -3.0846 | -3.8565 | |
EPS (Basic) Growth
| -57.96% | -55.05% | -20.04% | -25.02% | |
Basic Shares Outstanding
| 66.60M | 72.81M | 80.63M | 113.15M | |
EPS (Diluted)
| -1.6573 | -2.5697 | -3.0846 | -3.8565 | |
EPS (Diluted) Growth
| -57.96% | -55.05% | -20.04% | -25.02% | |
Diluted Shares Outstanding
| 66.60M | 72.81M | 80.63M | 113.15M | |
EBITDA
| (104.15M) | (180.68M) | (248.62M) | (477.88M) | |
EBITDA Growth
| -107.55% | -73.47% | -37.61% | -92.21% | |
EBITDA Margin
| -242.31% | -614.75% | -702.72% | -4,126.74% |
Snapshot
Average Recommendation | BUY | Average Target Price | 71.429 | |
Number of Ratings | 14 | Current Quarters Estimate | -1.004 | |
FY Report Date | 12 / 2024 | Current Year's Estimate | -3.489 | |
Last Quarter’s Earnings | -0.94 | Median PE on CY Estimate | N/A | |
Year Ago Earnings | -3.86 | Next Fiscal Year Estimate | -4.041 | |
Median PE on Next FY Estimate | N/A |
Earnings Per Share
This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
---|---|---|---|---|
# of Estimates | 14 | 9 | 15 | 15 |
Mean Estimate | -1.00 | -1.00 | -3.49 | -4.04 |
High Estimates | -0.93 | -0.74 | -3.38 | -3.25 |
Low Estimate | -1.15 | -1.12 | -3.98 | -4.65 |
Coefficient of Variance | -5.45 | -10.83 | -4.19 | -8.70 |
Analysts Recommendations
Current | 1 Month Ago | 3 Months Ago | |
---|---|---|---|
BUY | 13 | 14 | 14 |
OVERWEIGHT | 1 | 1 | 1 |
HOLD | 0 | 0 | 1 |
UNDERWEIGHT | 0 | 0 | 0 |
SELL | 0 | 0 | 0 |
MEAN | Buy | Buy | Buy |
SEC Filings for Revolution Medicines - RVMD
Filing Date | Type | Category | Amended |
---|---|---|---|
No results |
Insider Actions for Revolution Medicines - RVMD
Date | Name | Shares | Transaction | Value |
---|---|---|---|---|
Oct 4, 2024 | Mark A. Goldsmith See Remarks; Director | 302,192 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $44.8 per share | 13,538,201.60 |
Oct 4, 2024 | Mark A. Goldsmith See Remarks; Director | 300,170 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $45.46 per share | 13,645,728.20 |
Oct 4, 2024 | Mark A. Goldsmith See Remarks; Director | 310,170 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.09 per share | 1,268,595.30 |
Oct 4, 2024 | Mark A. Goldsmith See Remarks; Director | 271,229 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
Jul 18, 2024 | Stephen M. Kelsey See Remarks | 272,952 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $47.02 per share | 12,834,203.04 |
Jul 18, 2024 | Stephen M. Kelsey See Remarks | 276,752 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $46.08 per share | 12,752,732.16 |
Jul 18, 2024 | Stephen M. Kelsey See Remarks | 282,512 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $44.94 per share | 12,696,089.28 |
Jul 18, 2024 | Stephen M. Kelsey See Remarks | 284,640 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $43.99 per share | 12,521,313.60 |
Jul 18, 2024 | Stephen M. Kelsey See Remarks | 285,740 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.09 per share | 1,168,676.60 |
Jul 18, 2024 | Stephen M. Kelsey See Remarks | 73,332 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
Jul 18, 2024 | Stephen M. Kelsey See Remarks | 269,073 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $48.06 per share | 12,931,648.38 |
Jul 17, 2024 | Mark A. Goldsmith See Remarks; Director | 291,229 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
Jul 17, 2024 | Mark A. Goldsmith See Remarks; Director | 25,424 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $45.01 per share | 1,144,334.24 |
Jul 11, 2024 | Sushil Patel Director | 22,103 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $16.8 per share | 371,330.40 |
Jul 11, 2024 | Sushil Patel Director | 32,490 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
Jul 11, 2024 | Jeff Cislini General Counsel | 47,088 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $40.83 per share | 1,922,603.04 |
Jul 11, 2024 | Sushil Patel Director | 19,948 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $44 per share | 877,712.00 |
Jun 25, 2024 | Sandra J. Horning Director | 95,287 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
Jun 25, 2024 | Sandra J. Horning Director | 16,700 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
Jun 25, 2024 | Alexis A. Borisy Director | 2,336,294 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |